Profile data is unavailable for this security.
About the company
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing treatments for parties with cancers in need of new treatment options. Its product portfolio includes seclidemstat, an oral novel small molecule inhibitor of the LSD1 enzyme and the Company's lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options, and SP-3164, an oral small molecule protein degrader being developed for the treatment of Non-Hodgkins Lymphoma. SP-3164 is a small molecule protein degrader, and seclidemstat (SP-2577) is a small molecule inhibitor. SP-3164 is a next-generation cereblon-binding molecular glue (MG). SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold. The molecule was discovered using structure-based computational screening coupled with chemical screening and further optimization with structure-activity relationship studies.
- Revenue in USD (TTM)0.00
- Net income in USD-6.46m
- Incorporated2014
- Employees2.00
- LocationSalarius Pharmaceuticals Inc2450 Holcombe Blvd Ste J-608HOUSTON 77021-2041United StatesUSA
- Phone+1 (617) 874-1821
- Fax+1 (302) 655-5049
- Websitehttps://salariuspharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novelstem International Corp | 18.00k | -1.65m | 1.97m | 15.00 | -- | -- | -- | 109.39 | -0.0352 | -0.0352 | 0.0004 | -0.0541 | 0.0081 | -- | 8.00 | -- | -63.77 | -- | -- | -- | -- | -- | -7,867.33 | -- | -- | -2.13 | 2.61 | -- | 0.00 | -- | -446.84 | -- | -- | -- |
| VG Life Sciences Inc | 0.00 | -4.30m | 2.11m | 7.00 | -- | -- | -- | -- | -0.0721 | -0.0721 | 0.00 | -0.0491 | 0.00 | -- | -- | -- | -384.41 | -294.08 | -- | -- | -- | -- | -- | -587,591.90 | -- | -1.70 | -- | -- | -- | -- | 16.58 | -- | -- | -- |
| Dermata Therapeutics Inc | 0.00 | -9.82m | 2.13m | 8.00 | -- | 0.3384 | -- | -- | -19.42 | -19.42 | 0.00 | 4.79 | 0.00 | -- | -- | 0.00 | -140.74 | -- | -173.01 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.90 | -- | -- | -- |
| ELEVAI Labs Inc | 2.47m | -4.75m | 2.15m | 18.00 | -- | 0.7615 | -- | 0.8686 | -0.2698 | -0.2698 | 0.1408 | 0.1397 | 0.7249 | 1.04 | 95.33 | 137,407.20 | -139.23 | -- | -285.65 | -- | 69.25 | -- | -192.08 | -- | 0.5439 | -- | 0.00 | -- | 123.50 | -- | -138.94 | -- | -- | -- |
| Kiromic Biopharma Inc | 0.00 | -26.21m | 2.16m | 35.00 | -- | -- | -- | -- | -19.73 | -19.73 | 0.00 | -3.35 | 0.00 | -- | -- | 0.00 | -167.49 | -161.04 | -- | -294.57 | -- | -- | -- | -- | -- | -7.22 | 1.74 | -- | -- | -- | 33.00 | -- | 8.52 | -- |
| Bio Path Holdings Inc | 0.00 | -11.60m | 2.22m | 10.00 | -- | 1.54 | -- | -- | -17.91 | -17.91 | 0.00 | 0.5655 | 0.00 | -- | -- | 0.00 | -199.23 | -70.80 | -321.87 | -76.87 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -15.94 | -- | -- | -- |
| Zyversa Therapeutics Inc | 0.00 | -21.86m | 2.22m | 7.00 | -- | 0.2092 | -- | -- | -100.63 | -100.63 | 0.00 | 10.32 | 0.00 | -- | -- | 0.00 | -84.85 | -- | -140.95 | -- | -- | -- | -- | -- | -- | -21,828.74 | 0.00 | -- | -- | -- | -340.15 | -- | -- | -- |
| Aptevo Therapeutics Inc | 0.00 | -25.25m | 2.36m | 40.00 | -- | 0.1607 | -- | -- | -46.21 | -45.63 | 0.00 | 1.09 | 0.00 | -- | -- | 0.00 | -115.20 | -47.16 | -160.28 | -85.03 | -- | -- | -- | -583.47 | -- | -- | 0.00 | -- | -100.00 | -- | -365.90 | -- | -- | -- |
| Salarius Pharmaceuticals Inc | 0.00 | -6.46m | 2.36m | 2.00 | -- | 0.4427 | -- | -- | -12.64 | -12.64 | 0.00 | 3.70 | 0.00 | -- | -- | 0.00 | -82.83 | -69.27 | -119.83 | -79.89 | -- | -- | -- | -675.70 | -- | -- | 0.00 | -- | -- | -- | 60.32 | -- | -- | -- |
| Bluejay Diagnostics Inc | 0.00 | -9.40m | 2.36m | 10.00 | -- | 0.0427 | -- | -- | -44.53 | -44.53 | 0.00 | 3.34 | 0.00 | -- | -- | 0.00 | -97.27 | -- | -121.76 | -- | -- | -- | -- | -- | -- | -19.61 | 0.0185 | -- | -100.00 | -- | -7.07 | -- | -- | -- |
| Qrons Inc | 0.00 | -860.04k | 2.59m | 2.00 | -- | -- | -- | -- | -0.0632 | -0.0632 | 0.00 | -0.088 | 0.00 | -- | -- | 0.00 | -9,368.63 | -1,513.45 | -- | -- | -- | -- | -- | -- | -- | -9.21 | -- | -- | -- | -- | -7.61 | -- | -- | -- |
| Protagenic Therapeutics Inc | 0.00 | -6.40m | 2.63m | 1.00 | -- | 3.32 | -- | -- | -1.45 | -1.45 | 0.00 | 0.1774 | 0.00 | -- | -- | 0.00 | -152.72 | -74.49 | -206.36 | -92.56 | -- | -- | -- | -- | -- | -17.09 | 0.00 | -- | -- | -- | -40.64 | -- | -- | -- |
| GB Sciences Inc | 0.00 | -1.64m | 2.65m | 2.00 | -- | -- | -- | -- | -0.0041 | -0.0041 | 0.00 | -0.0131 | 0.00 | -- | -- | 0.00 | -597.54 | -31.80 | -- | -297.29 | -- | -- | -- | -- | -- | -6.49 | -- | -- | -- | -- | 60.24 | -- | -- | -- |
| Revelation Biosciences Inc | 0.00 | -15.90m | 2.71m | 9.00 | -- | 1.04 | -- | -- | -29.75 | -29.75 | 0.00 | 0.6939 | 0.00 | -- | -- | 0.00 | -112.35 | -- | -253.32 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 98.89 | -- | -- | -- |
Data as of Sep 24 2024. Currency figures normalised to Salarius Pharmaceuticals Inc's reporting currency: US Dollar USD
2.92%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 31 Mar 2024 | 10.50k | 1.76% |
| Horizon Kinetics Asset Management LLCas of 31 Mar 2024 | 3.89k | 0.65% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.82k | 0.31% |
| Tower Research Capital LLCas of 31 Mar 2024 | 1.05k | 0.18% |
| Osaic Wealth, Inc. (Investment Management)as of 31 Mar 2024 | 163.00 | 0.03% |
| Securities America Advisors, Inc.as of 31 Mar 2024 | 10.00 | 0.00% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 8.00 | 0.00% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 4.00 | 0.00% |
| Merrill Lynch, Pierce, Fenner & Smith, Inc. (Invt Mgmt)as of 31 Mar 2024 | 2.00 | 0.00% |
| UBS Financial Services, Inc.as of 31 Mar 2024 | 2.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
